Alkermes plc (ALKS)
$
30.61
+0.36 (1.18%)
Key metrics
Financial statements
Free cash flow per share
2.9471
Market cap
5 Billion
Price to sales ratio
3.3345
Debt to equity
0.0490
Current ratio
3.3332
Income quality
1.4517
Average inventory
183.2 Million
ROE
0.2541
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alkermes plc, a biopharmaceutical company founded in 1987 and headquartered in Dublin, Ireland, focuses on researching, developing, and commercializing pharmaceutical products to meet the unmet medical needs of patients in various therapeutic areas. The company has a strong market presence, reporting substantial revenue of $1,557,632,000.00 which underscores its operational success. The EBITDA ratio stands at 0.32 highlighting the company's operational efficiency. Furthermore, the earnings per share (EPS) is reported at $2.22 indicating profitability on a per-share basis. Alkermes also earned an interest income of $42,450,000.00 showcasing its ability to generate returns from financial investments. Additionally, the net total of other income and expenses is reported at $23,114,000.00 reflecting the impact of non-core financial activities on the overall financial standing of the company. Among its marketed products are ARISTADA, VIVITROL, and VUMERITY, which address critical psychiatric and neurological conditions, emphasizing the company’s commitment to addressing diverse health challenges. Positioned as a key player in the Biotechnology industry, Alkermes contributes significantly to the overall market landscape while belonging to the Healthcare sector, driving innovation and growth. The stock is affordable at $30.25 making it suitable for budget-conscious investors. With a mid-range market capitalization of $5,047,619,610.00 the company is considered a steady performer in the market. Furthermore, the stock has a high average trading volume of 1,774,033.00 indicating strong liquidity and investor interest. Alkermes demonstrates a robust portfolio that includes not only marketed products but also promising drug candidates in development, such as LYBALVI and nemvaleukin alfa, which aim to further expand the treatment options available to patients.
Is Alkermes plc (ALKS) a good investment?
Investing in Alkermes plc (ALKS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Alkermes plc (ALKS)'s stock forecast?
Analysts predict Alkermes plc stock to fluctuate between $22.90 (low) and $36.45 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alkermes plc's market capitalization?
As of 2025-05-30, Alkermes plc's market cap is $5,047,619,610, based on 164,901,000 outstanding shares.
How does Alkermes plc compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Alkermes plc has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alkermes plc (ALKS) stock?
To buy Alkermes plc (ALKS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALKS. Place an order (Market, Limit, etc.).
What is the best time to invest in Alkermes plc?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Alkermes plc stock ever split?
Alkermes plc's last stock split was 2:1 on 2000-05-15.
How did Alkermes plc perform in the last earnings report?
Revenue: $1,557,632,000 | EPS: $2.22 | Growth: 3.74%.
Where can I find Alkermes plc's investor relations reports?
Visit https://www.alkermes.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alkermes plc?
You can explore historical data from here
What is the all-time high and low for Alkermes plc stock?
All-time high: $36.45 (2025-02-18) | All-time low: $18.02 (2021-03-05).
What are the key trends affecting Alkermes plc stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The ongoing phase 3 ENLIGHTEN-Youth trial aims to evaluate LYBALVI's efficacy and safety in pediatric patients, with a primary completion date of September 2026. Long-term data indicates minimal weight gain with LYBALVI, addressing a major concern with mental health medications and supporting its market potential.
seekingalpha.com
Alkermes plc (NASDAQ:ALKS ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Blair Jackson - Executive Vice President and Chief Operating Officer Craig Hopkinson - Chief Medical Officer Conference Call Participants Joseph Thome - TD Cowen Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Jason Gerberry - Bank of America Leonid Timashev - RBC Capital Markets Uy Ear - Mizuho Securities Joel Beatty - Baird David Hoang - Deutsche Bank Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to Alkermes' First Quarter 2025 Financial Results Conference Call.
zacks.com
Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago.
zacks.com
ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.
zacks.com
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
investors.com
GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility. The post GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait appeared first on Investor's Business Daily.
zacks.com
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
seekingalpha.com
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
See all news
